vs
Side-by-side financial comparison of Alkermes plc. (ALKS) and UNITED FIRE GROUP INC (UFCS). Click either name above to swap in a different company.
Alkermes plc. is the larger business by last-quarter revenue ($384.5M vs $365.8M, roughly 1.1× UNITED FIRE GROUP INC). On growth, UNITED FIRE GROUP INC posted the faster year-over-year revenue change (9.8% vs -10.6%). Over the past eight quarters, UNITED FIRE GROUP INC's revenue compounded faster (11.2% CAGR vs 4.8%).
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio.
The United Fruit Company was an American multinational corporation that traded in tropical fruit grown on Latin American plantations and sold in the United States and Europe. The company was formed in 1899 from the merger of the Boston Fruit Company with Minor C. Keith's banana-trading enterprises. It flourished in the early and mid-20th century, and it came to control vast territories and transportation networks in Central America, the Caribbean coast of Colombia, and the West Indies. Althou...
ALKS vs UFCS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $384.5M | $365.8M |
| Net Profit | $49.3M | — |
| Gross Margin | 88.0% | — |
| Operating Margin | 15.1% | 13.2% |
| Net Margin | 12.8% | — |
| Revenue YoY | -10.6% | 9.8% |
| Net Profit YoY | -66.3% | — |
| EPS (diluted) | $0.29 | $1.45 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $384.5M | $365.8M | ||
| Q3 25 | $394.2M | $354.0M | ||
| Q2 25 | $390.7M | $335.5M | ||
| Q1 25 | $306.5M | $331.1M | ||
| Q4 24 | $430.0M | $333.2M | ||
| Q3 24 | $378.1M | $323.0M | ||
| Q2 24 | $399.1M | $301.2M | ||
| Q1 24 | $350.4M | $296.0M |
| Q4 25 | $49.3M | — | ||
| Q3 25 | $82.8M | $39.2M | ||
| Q2 25 | $87.1M | $22.9M | ||
| Q1 25 | $22.5M | $17.7M | ||
| Q4 24 | $146.5M | — | ||
| Q3 24 | $92.4M | $19.7M | ||
| Q2 24 | $91.4M | $-2.7M | ||
| Q1 24 | $36.8M | $13.5M |
| Q4 25 | 88.0% | — | ||
| Q3 25 | 86.9% | — | ||
| Q2 25 | 87.3% | — | ||
| Q1 25 | 83.9% | — | ||
| Q4 24 | 85.6% | — | ||
| Q3 24 | 83.3% | — | ||
| Q2 24 | 84.6% | — | ||
| Q1 24 | 83.3% | — |
| Q4 25 | 15.1% | 13.2% | ||
| Q3 25 | 22.6% | 13.7% | ||
| Q2 25 | 23.8% | 8.7% | ||
| Q1 25 | 4.5% | 6.6% | ||
| Q4 24 | 37.8% | 11.9% | ||
| Q3 24 | 27.7% | 7.7% | ||
| Q2 24 | 27.5% | -1.3% | ||
| Q1 24 | 12.4% | 5.5% |
| Q4 25 | 12.8% | — | ||
| Q3 25 | 21.0% | 11.1% | ||
| Q2 25 | 22.3% | 6.8% | ||
| Q1 25 | 7.3% | 5.3% | ||
| Q4 24 | 34.1% | — | ||
| Q3 24 | 24.4% | 6.1% | ||
| Q2 24 | 22.9% | -0.9% | ||
| Q1 24 | 10.5% | 4.6% |
| Q4 25 | $0.29 | $1.45 | ||
| Q3 25 | $0.49 | $1.49 | ||
| Q2 25 | $0.52 | $0.87 | ||
| Q1 25 | $0.13 | $0.67 | ||
| Q4 24 | $0.88 | $1.22 | ||
| Q3 24 | $0.55 | $0.76 | ||
| Q2 24 | $0.53 | $-0.11 | ||
| Q1 24 | $0.21 | $0.52 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $388.6M | $156.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.8B | $941.2M |
| Total Assets | $2.5B | $3.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $388.6M | $156.3M | ||
| Q3 25 | $616.4M | $233.7M | ||
| Q2 25 | $521.2M | $202.1M | ||
| Q1 25 | $399.8M | $183.7M | ||
| Q4 24 | $291.1M | $200.9M | ||
| Q3 24 | $396.3M | $197.4M | ||
| Q2 24 | $535.1M | $153.4M | ||
| Q1 24 | $420.8M | $217.8M |
| Q4 25 | $1.8B | $941.2M | ||
| Q3 25 | $1.7B | $898.7M | ||
| Q2 25 | $1.6B | $845.7M | ||
| Q1 25 | $1.5B | $817.7M | ||
| Q4 24 | $1.5B | $781.5M | ||
| Q3 24 | $1.3B | $785.8M | ||
| Q2 24 | $1.3B | $726.6M | ||
| Q1 24 | $1.3B | $736.8M |
| Q4 25 | $2.5B | $3.8B | ||
| Q3 25 | $2.3B | $3.8B | ||
| Q2 25 | $2.3B | $3.7B | ||
| Q1 25 | $2.1B | $3.5B | ||
| Q4 24 | $2.1B | $3.5B | ||
| Q3 24 | $2.2B | $3.5B | ||
| Q2 24 | $2.2B | $3.4B | ||
| Q1 24 | $2.1B | $3.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $170.1M | $269.7M |
| Free Cash FlowOCF − Capex | $170.0M | — |
| FCF MarginFCF / Revenue | 44.2% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | 3.45× | — |
| TTM Free Cash FlowTrailing 4 quarters | $480.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $170.1M | $269.7M | ||
| Q3 25 | $101.7M | $60.8M | ||
| Q2 25 | $150.2M | $53.4M | ||
| Q1 25 | $98.8M | $35.7M | ||
| Q4 24 | $190.4M | $340.3M | ||
| Q3 24 | $81.6M | $56.5M | ||
| Q2 24 | $146.0M | $91.3M | ||
| Q1 24 | $21.1M | $36.2M |
| Q4 25 | $170.0M | — | ||
| Q3 25 | $84.4M | — | ||
| Q2 25 | $137.2M | — | ||
| Q1 25 | $88.7M | — | ||
| Q4 24 | $180.6M | — | ||
| Q3 24 | $73.3M | — | ||
| Q2 24 | $138.9M | — | ||
| Q1 24 | $12.8M | — |
| Q4 25 | 44.2% | — | ||
| Q3 25 | 21.4% | — | ||
| Q2 25 | 35.1% | — | ||
| Q1 25 | 28.9% | — | ||
| Q4 24 | 42.0% | — | ||
| Q3 24 | 19.4% | — | ||
| Q2 24 | 34.8% | — | ||
| Q1 24 | 3.6% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 4.4% | — | ||
| Q2 25 | 3.3% | — | ||
| Q1 25 | 3.3% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 2.2% | — | ||
| Q2 24 | 1.8% | — | ||
| Q1 24 | 2.4% | — |
| Q4 25 | 3.45× | — | ||
| Q3 25 | 1.23× | 1.55× | ||
| Q2 25 | 1.72× | 2.33× | ||
| Q1 25 | 4.40× | 2.02× | ||
| Q4 24 | 1.30× | — | ||
| Q3 24 | 0.88× | 2.86× | ||
| Q2 24 | 1.60× | — | ||
| Q1 24 | 0.57× | 2.68× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALKS
| Vivitrol | $124.1M | 32% |
| Aristada And Aristada Initio | $97.2M | 25% |
| LYBALVI | $94.1M | 24% |
| Royalty | $65.7M | 17% |
| Manufacturing Revenue | $3.3M | 1% |
UFCS
Segment breakdown not available.
